Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

June 30, 2002

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

atrasentan hydrochloride

Trial Locations (10)

19104

Abramson Cancer Center at University of Pennsylvania Medical Center, Philadelphia

30322

Winship Cancer Institute of Emory University, Atlanta

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

48202

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit

35294-3300

University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham

33612-9497

H. Lee Moffitt Cancer Center and Research Institute, Tampa

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

02114

Massachusetts General Hospital Cancer Center, Boston

27157-1082

Comprehensive Cancer Center at Wake Forest University, Winston-Salem

78284-7811

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00017264 - Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma | Biotech Hunter | Biotech Hunter